Post-transplantation cyclophosphamide (PTCy) is widely used for graft-versus-host disease (GVHD) prophylaxis in haploidentical hematopoietic stem cell transplantation. Although the standard dose is 100 mg/kg over 2 days, reduced-dose schedules with preserved GVHD control have been explored [ 1 , 2 , 3 , 4 , 5 ].
Association of ideal body weight–normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight/obesity — 科研速览 Science Skim